# NIH Reporter #3R34AI198088-01S5

Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial

**Recipient:** University of Rochester, School of Medicine & Dentistry

**Award Amount:** $11,873.00
**Ceiling:** $11,873.00

**Awarded:** September 14, 2026

**Identifier:** 3R34AI198088-01S5

A phase III clinical trial funded by NIH to test aggressive antipyretic therapy in children with CNS malaria, aiming to reduce mortality and neurodisability.

### Description

This project involves a phase III clinical trial to evaluate the efficacy of adjunctive aggressive antipyretic therapy in children with CNS malaria. The study is funded by NIH and conducted by the University of Rochester. The primary outcome measures include mortality, neurodisability, and epilepsy within 3 years post-infection.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11604392)